Citations

Abstract The acetabular labrum is a fibrocartilaginous structure that deepens the acetabular socket and helps maintain a suction seal. In patients with hip dysplasia, a distinct labral tear pattern called an inside‐out labral tear is often seen. This tear pattern is particularly challenging to correct via conventional techniques since the labrum can potentially remain everted and insufficiently restore the native hip labral suction seal after repair. An inverted hip labral repair technique is performed for this pathology at our institution and focuses on achieving optimal labral orientation to enhance the suction seal and joint stability, particularly in dysplastic hips. This Technical Note aims to describe the key surgical principles and clinical considerations of inverted hip labral repair. Technique Video video See video under supplementary data.

Abstract INTRODUCTION In multicenter Alzheimer's disease studies, amyloid positron emission tomography (PET) visual reads are typically performed centrally by a few experts. Incorporating a broader reader network enhances scalability and generalizability. METHODS Ten neuroimaging experts from eight Alzheimer's Disease Research Centers (ADRCs) visually read 180 amyloid PET scans (30 scans and 15 duplicate scans for each of four tracers, imaged across a wide variety of scanners), using preferred reading software without anatomical imaging or quantitation. Scans were classified as elevated or non‐elevated per tracer‐specific criteria. Inter‐ and intra‐rater agreement was assessed. RESULTS Inter‐rater agreement was substantial (Fleiss’ κ = 0.78), with full consensus on 69% of scans. Inter‐rater reliability was substantial to perfect across tracers (Fleiss’ κ = 0.70–0.87). Intra‐rater agreement was substantial to perfect (Cohen's κ = 0.79‐1). Scans with intermediate (10–40 Centiloid) quantitation had lower reader agreement. DISCUSSION A multicenter expert network achieved substantial agreement classifying amyloid PET scans. These scans provide a standard for reader training and reliability assurance in future studies. Highlights Calibration methods ensure reliable amyloid positron emission tomography (PET) visual reads across multiple raters. Substantial agreement is possible across readers using their preferred tools. Agreement is also substantial regardless of the amyloid PET tracer used. Scans with intermediate (10–40 Centiloid) quantitation have lower reader agreement. The calibration set will become a training tool for amyloid PET visual read studies.

Abstract Background Hospital discharge summaries are critical for ensuring continuity of care, but their quality often varies. Large language models (LLMs) have the potential to standardize and enhance the efficiency of this documentation process. Objectives To evaluate the quality of hospital discharge summaries created by an LLM‐based hospital course drafting tool created by Epic Systems compared with human‐written summaries. Methods Retrospective study at a single tertiary‐care institution in 2024. The cohort included 100 adult hospitalizations lasting >72 h across medical and surgical dismissing services. No interventions were performed. Summaries (LLM‐generated vs. human‐written) were independently reviewed using a standardized rubric covering nine domains (e.g., comprehensiveness, clarity, relevance). Scores were normalized and compared. Readability was assessed using Flesch Reading Ease. Results LLM‐generated summaries outperformed human‐written summaries across all criteria ( p < .05), with the greatest difference observed in comprehensiveness (LLM median 0.62 vs. human −0.23). Human‐written summaries from surgical services scored lower than those from medical services, but LLM performance was consistent across both. Human summaries had higher Flesch Reading Ease scores (33.11 vs. 26.2; p < .05), reflecting simpler language. Conclusions LLM‐generated summaries demonstrated superior quality, consistency, and clinical utility compared with human‐written summaries, highlighting their potential to improve documentation efficiency and standardization.

AimsThe aim of this study was to compare the early clinical outcomes of robotically-assisted total knee arthroplasty (RA-TKA) and manual total knee arthroplasty (M-TKA), using daily remote patient monitoring.MethodsWe prospectively enrolled and compared patients who underwent 95 RA-TKAs with those who underwent 114 M-TKAs. All patients used an activity monitor and a patient engagement platform for two weeks preoperatively and 90 days postoperatively to collect daily visual analogue scale (VAS) pain scores, opioid consumption (in morphine milligram equivalents (MMEs)), step counts, weekly Oxford Knee Scores (OKSs), and monthly Forgotten Joint Scores (FJS). There were no significant differences between groups in sex or BMI. Patients in the RA-TKA group were significantly younger (mean age 63 vs 65 years; p = 0.006). Independent-samples t-tests, chi-squared tests, and Fisher’s exact tests were used for statistical analysis.ResultsRA-TKA led to significantly decreased pain (mean VAS 3.6 vs 4.2; p = 0.011) and significantly reduced opioid consumption in the first seven days postoperatively (a mean of 10 less MMEs per day; p < 0.001) compared with M-TKA. The RA-TKA group stopped taking opioids six days sooner (mean 24 days vs 30 days; p = 0.041). There were no significant differences in the number of days before stopping the use of walking aids (mean 31 days vs 35 days; p = 0.091). Patients in the RA-TKA group had significantly increased OKSs for the first five weeks (p = 0.013). There were no significant differences in the FJSs at all times or in OKSs beyond five weeks. There were no significant differences in the operating times (p = 0.405), step counts (p = 0.642), or complications (p = 0.222) between the groups.ConclusionThe use of robotic assistance in TKA led to significant improvements in pain, opioid consumption, and OKSs compared with manual instrumentation in the early recovery after primary TKA.Cite this article: Bone Joint J 2025;107-B(10):1054–1063.

Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver disease characterized by complex interactions between lipotoxicity, ER stress responses, and immune-mediated inflammation. We identified enrichment of the proinflammatory alarmin S100 calcium-binding protein A11 (S100A11) on extracellular vesicles stimulated by palmitate-induced lipotoxic ER stress with concomitant upregulation of hepatocellular S100A11 abundance in an IRE1A-XBP1s–dependent manner. We next investigated the epigenetic mechanisms that regulate this stress response. Publicly available human liver ChIP-Seq GEO datasets demonstrated a region of histone H3 lysine 27 (H3K27) acetylation upstream of the S100A11 promoter. H3K27 acetylation ChIP-qPCR demonstrated a positive correlation between lipotoxic ER stress and H3K27 acetylation of the region, which we termed the lipotoxicity-influenced enhancer (LIE) domain. CRISPR-mediated repression of the LIE domain reduced palmitate-induced H3K27 acetylation and corresponding S100A11 upregulation in Huh7 cells and immortalized mouse hepatocytes. Silencing of the murine LIE in 2 independent steatohepatitis models demonstrated reduced S100a11 upregulation and attenuated liver injury. We confirmed H3K27 acetylation and XBP1s occupancy at the LIE domain in human MASH liver samples and an increase in hepatocyte-derived S100A11-enriched extracellular vesicles in MASH patient plasma. Our studies demonstrate a LIE domain that mediates hepatic S100A11 upregulation. This pathway may be a potential therapeutic target in MASH.

PURPOSE Older patients with ALL receiving conventional chemotherapy have poor survival due to toxic death and relapse. We hypothesized that a chemotherapy-free, targeted regimen using the anti-CD22 antibody-calicheamicin conjugate inotuzumab ozogamicin followed by the bispecific anti-CD19/CD3 T-cell engager blinatumomab would reduce toxic death and yield high rates of prolonged remission and survival. METHODS Eligible patients were age 60 years and older with untreated, Philadelphia chromosome (Ph)–negative, CD22-positive, B-cell ALL. Patients received up to two cycles of inotuzumab ozogamicin followed by four or five cycles of blinatumomab with intrathecal methotrexate CNS prophylaxis. The primary end point was 1-year event-free survival (EFS). RESULTS The 33 eligible patients had a median age of 71 years (range, 60-84) and a median CD22 expression of 92% (range, 21%-100%). Eight (24%) had previous chemotherapy or radiation for other cancers, six for multiple myeloma. The composite complete remission rate was 85% after two cycles of inotuzumab ozogamicin and 97% by the end of two cycles of blinatumomab. At a median follow-up of 30 months, the 1-year EFS and overall survival were 75% (95% CI, 61 to 92) and 85% (95% CI, 73 to 98), respectively. EFS was shorter with lower CD22 expression or detectable measurable residual disease at any time point. CONCLUSION Inotuzumab ozogamicin then blinatumomab without maintenance chemotherapy in older patients with untreated, Ph-negative, CD22-positive, B-cell ALL yields a high remission rate and excellent EFS. Given the lack of standard, safe, and effective therapies in this population, the regimen should be considered a standard treatment option.

PURPOSE Leptomeningeal metastatic disease (LMD) is associated with poor prognosis and imposes severe symptomatic limitations on functional status and quality of life. In recent years, the range of diagnostic and therapeutic options available to patients with LMD has expanded, but the impact of these innovations on clinical characteristics and outcomes remains unclear. We conducted a retrospective study to define the LMD patient population, symptoms experienced, and the frequency of accessing specialty palliative care (PC) services, at a large tertiary referral center. METHODS We conducted a retrospective electronic medical record review on the basis of a convenience sample of 104 patients diagnosed and treated with LMD with dates of diagnosis between January 1, 2016, and October 1, 2022. Variables were generated on the basis of patient demographics, reported symptoms, and clinical course. Data were analyzed using Stata 16. RESULTS Of 104 patients in the analysis, the most common symptoms reported were headache and extremity weakness (52% of patients reported each). The mean number of weeks between LMD diagnosis and date of death was 41.4, with a median of 27.9 weeks, and a range of 1.4-143.4 weeks. Forty-five percent of patients had at least one documented visit with an inpatient or outpatient PC provider. CONCLUSION Patients with an LMD diagnosis face a high symptom burden. Our findings highlight that prognosis may be longer than what is typically quoted in the literature, but further study would be needed to understand this discrepancy. Fewer than half of the patients in our sample had a documented visit with a PC specialist, suggesting a missed opportunity in this population to connect with providers specialized in managing symptom burden and doing nuanced advance care planning.